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“On n’explique qu’en comparant”. 
– Emile Durkheim

ABSTRACT
Legionnaires’ disease (LD) is a water-borne infection cause by Gram-negative 
bacteria Legionella spp. with virtually no person-to-person transmission. The 
clinical presentation is a severe pneumonia with a case fatality of approximately 
10%. Known risk factors include increasing age, chronic lung disease and various 
conditions associated with immunodeficiency. Most cases are community-acquired 
and sporadic. LD is notifiable in the European Union (EU) and European Economic 
Area (EEA). LD incidence is thought to be increasing in Europe and the USA for 
reasons not fully understood, including climate change, changing demographics 
and improved surveillance. The overarching aim of this thesis was to explore vari-
ous aspects of LD epidemiology, prevention and control using surveillance data.
In study I, we retrieved travel-associated Legionnaire’s disease (TALD) surveillance 
data for 2009 from the European Surveillance System, and tourism denominator 
data from the Statistical Office of the European Union. We estimated the risk for 
TALD in several European countries and highlighted potential under-ascertainment 
of LD in some countries.
To confirm and generalize findings of studies performed at regional or national 
level, we investigated the effect of temperature, rainfall, and atmospheric pressure 
on short-term variations in LD notification rate in Denmark, Germany, Italy, and 
the Netherlands in Study II. We fitted Poisson regression models to estimate the 
association between meteorological variables and the weekly number of community-
acquired LD cases. We found that the higher risk was associated with simultaneous 
increase in temperature and rainfall. These findings contributed to the growing 
evidence supporting a possible impact of climate change on LD incidence.
In Study III, we investigate the actors associated with LD recurrence in hotels. 
We conducted a retrospective cohort analysis and use survival analysis methods 
to estimate the association between hotels characteristics and the occurrence of a 
further case. We found that hotel size and previous association with multiple cases 
were predictors of the occurrence of a further case. This study also highlighted 
weaknesses in data collected in the surveillance scheme.
In Study IV, we used a large sample of LD over a 10-year period to look more 
closely at healthcare-associated (HCA) LD. We found that HCA LD cases are 
responsible for a major part of LD and differ from community-acquired cases in 
many aspects, including demographics, causative strains and outcome.
Taken together, the findings support the use of surveillance data for research pur-
poses. They shed light on some epidemiological aspects of LD and inform the 
surveillance system for possible improvements.
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11 INTRODUCTION
Legionnaires’ disease (LD) is a severe pneumonia caused by Legionella species (spp). 
These Gram-negative bacteria can be found in freshwater environments worldwide 
and often contaminate man-made water systems (1). The first description of the 
disease and its name came after a large outbreak among members of the American 
Legion in 1976 (2). People are infected by inhalation or less frequently by aspira-
tion of aerosols containing Legionella, most commonly L. pneumophila serogroup 
1 (1). Nonetheless, some other species may be involved as suggested by the reported 
association between handling potting soil and infection with L. longbeachae (3).
Although not common in outpatients, LD is one of the most common causative 
factor in community-acquired pneumonia admitted to intensive care units (ICU) 
(4). In Europe, 5000 to 7000 LD cases are reported each year, of which approxi-
mately 10% die. A limited number of countries account for most cases (5). Since 
2011, the average notification rate increased from 0.97 to 1.2 LD cases per 100,000 
population but masked important differences across countries. In many central and 
eastern European countries, notification rates were below 1 per million population, 
unlikely to reflect the local risk for LD. This could probably be explained by poor 
awareness among clinicians, limited diagnostic capability or capacity and low 
reporting (6). Approximately 70% of all reported cases are community-acquired, 
20% travel-associated and 10% healthcare-related (5). Known risk factors were male 
sex, increasing age and various conditions associated with immunodeficiency (7). 
Since the first description of the disease, most reported cases were sporadic but 
large outbreaks continued to occur. In 2001, 449 confirmed cases were reported in 
Murcia (Spain) in relation with a cooling tower (8). It is to date the largest outbreak 
ever reported. More recently, a large community outbreak occurred in Vila Franca 
de Xira near Lisbon, Portugal in 2014 (9). With nearly 400 cases, it was one of the 
largest outbreaks ever observed in Europe. The investigation identified industrial 
wet cooling systems to be the probable source of infection. 
Outside of Europe, epidemiological information is also mostly provided by surveil-
lance data. Surveillance schemes for LD are in place in North America (Canada 
and United States of America (USA)) and in other developed countries such as 
Australia or Japan but limited data are available from other parts of the world (7). 
In countries with available data, the main demographics of LD are similar to those 
observed in Europe (10). 
For years, much of the attention focused on travel-associated cases (TALD) clus-
ters and large community-acquired outbreaks because their detection prompted 
immediate control measures. Nonetheless, sources of the infection were seldom 
ascertained and outbreak investigation remains very challenging. In addition, rela-
tively little is known on sporadic community-acquired or healthcare-associated 
cases. Environmental risk factors, especially of sporadic community-acquired LD 
remain poorly understood. 
22 BACKGROUND
2.1 Microbiology
Legionellae are aerobic, Gram-negative, non-spore-forming gammaproteo-
bacteria (11). Most human infection are caused by L. pneumophila serogroup 1 
but numerous other species have been isolated in the environment and many of 
them are pathogenic in humans (12). There are 58 species in the genus Legionella, 
of which approximately 30 can cause infection in humans (13). However, it seems 
that most infections caused by Legionella species other than L. pneumophila occur 
in immunocompromised patients. 
There is evidence that Legionella can virtually be found in any water environment 
whether natural or altered (1). Conversely, Legionella does not survive in dry 
environments. Water temperature plays an important role in in Legionella bacterial 
development. Katz et al showed that L. pneumophila multiplies at temperatures 
between 25 and 42°C (14). Under certain conditions, it may even be possible for 
mutant strains to grow below 20°C (15). At lower temperatures, Legionella will 
survive without multiplying (16). The alteration of aquatic environments by tem-
perature could modify the balance between protozoa and bacteria, favoring the 
growth of Legionella (1).
In the environment, Legionella can be associated with complex biofilms or other 
microorganisms such as amoebae (1, 11). These associations can provide protec-
tion against extreme conditions, such as high or low temperature or the presence 
of chemical agents active against Legionella (e.g. chlorine).
Previous studies have suggested an impact of environmental conditions on LD 
incidence. Contributions of temperature, humidity or precipitation have been 
reported in studies with different methodologies and settings (17-24). Conclusions 
were at times divergent and the real impact of climate on LD incidence remains to 
be validated. Theoretically, any weather condition favoring the growth Legionella 
spp. or its presence in aerosols could potentially be associated with a higher LD 
incidence. Since climate change is expected to bring both an increase in heavy 
rainfall and higher temperatures, it is important to better understand the impact 
of weather on LD incidence (25).
2.2 Transmission
People are infected by inhaling aerosols contaminated by Legionella. Person-to-
person transmission has been described only once (26). In most cases, contami-
nated aerosols contain L. pneumophila serogroup 1 (1) . Other species such as L. 
longbeachae are thought to infect people through other routes although yet not 
fully understood. Exposure to potting soils or compost, poor hand-washing after 
gardening activities may be associated with LD caused by L. longbeachae (27). 
3Several potential sources of infection have been identified, including cooling towers, 
hot and cold-water systems, spa and thermal pools, springs, humidifiers, domestic 
plumbing, sewage, potting mixes, and compost (16). A study has even suggested 
that the use of windscreen wiper fluid without added screenwash in motor vehicles 
could be a risk factor for LD (28). Other unusual transmission routes have also 
been reported. A humidifier filled with tap water caused the infection in an infant 
aged below 6 months (29).
2.3 Clinical presentation
Two forms of infection with Legionella are classically described under the term of 
Legionellosis. The pneumonic form is the Legionnaires’ disease whilst Pontiac fever 
is a milder form of the infection without pneumonia, usually described as a self-
limited influenza-like illness. Both incubation and duration of the disease are shorter 
for Pontiac fever (7). Pontiac fever is not notifiable in Europe and most cases are 
diagnosed during outbreaks when mild or asymptomatic cases are investigated (30).
The incubation period of LD is thought to be 2-10 days with a median of 7 days 
(7). However, shorter and longer incubations have been reported in outbreak 
reports. Thus, during the large outbreak that affected visitors of a flower show in 
the Netherlands in 1999, incubation periods ranged from 2 to 19 days (31).
LD is a severe pneumonia and its clinical and radiographic presentations are very 
difficult to distinguish from pneumonia caused by more common pathogens such 
as Streptococcus pneumonia (32, 33). It usually starts with a prodromal illness 
that may include unspecific symptoms such as headache, myalgia, asthenia, and 
anorexia. Respiratory symptoms may include cough, dyspnea, and chest pain. 
Cough does not systematically produce purulent sputum, which is a useful mate-
rial for laboratory confirmation of the infection. Gastrointestinal and neurological 
symptoms are not uncommon (13). Other systemic disorders are common such 
as impaired renal and liver functions. Atypical presentations have been reported 
including cases with complete absence of respiratory symptoms (34).
2.4 Diagnosis and treatment
2.4.1 Diagnosis
The identification of the causative agent of LD – L. pneumophila – during the 
historical outbreak that stroke members of the American Legion was done by 
detecting specific antibodies in the serum of patients (35). Alongside culture, 
serology has been the main laboratory test used for diagnosis of LD in the early 
years of its history (11). In the past two decades, the urinary antigen test (UAT) 
has become the most used diagnostic test for LD. In Europe, it is approximately 
80% of LD cases that are diagnosed with UAT (5). Some large reporting countries 
4such as Italy or Spain rely almost exclusively on UAT with 90-95% of their LD 
cases reported with UAT. The main limitation of UAT is that it only captures L. 
pneumophila serogroup 1. It means that infections caused by other species may 
remain underdiagnosed. However, the large diffusion of a convenient test such as 
UAT can also be beneficial. Thus, since its introduction in 1996 in Catalonia, Spain, 
community outbreaks were detected earlier and the case fatality decreased (36). 
The isolation of Legionella spp. from respiratory secretions or any normally sterile 
site (i.e. culture) remains the gold standard. Before the era of PCR, culture was the 
sole method that would allow for matching clinical and environmental isolates. In 
recent years, only 10% of cases reported in Europe were culture-confirmed (5). 
This overall proportion masked important differences across countries. In 2015, 
some countries did not report any culture confirmations while 41% of LD cases 
reported by Denmark were culture-confirmed (37).
In Europe, an increasing number of LD cases have been reported with a diagno-
sis made by polymerase chain reaction (PCR). In 2015, the proportion of PCR 
ascertained LD cases was over 75% in Denmark (37). A study in New Zealand 
has suggested that the routine use of PCR had improved the detection of LD cases 
caused by Legionella spp. (mainly L. longbeachae) (38).
Other laboratory tests used in Europe include the detection of L. pneumophila 
antigen in respiratory secretions or lung tissue and serological methods. The 
use of these methods is now declining and becoming increasingly marginal (5). 
Figure 1 summarizes the type of specimens and diagnostic tests that can be used 
for detecting Legionella infections. 
Figure 1. Type of specimens and diagnostic tests for detecting Legionella infections. 
Source: Chaudhry (2018) (39)
52.4.2 Treatment
Antibiotics with good intracellular action are effective against any form of legionel-
losis. Azithromycin (macrolide) and levofloxacin (quinolone) are the best first-line 
option (40, 41). β-lactam antibiotics are not active against Legionella. This is of 
importance since β-lactam antibiotics are usually the first-line treatment for com-
munity-acquired pneumonia. So far, very few Legionella strains have been reported 
with a reduced susceptibility to antibiotics with intracellular activity. One clinical 
isolate resistant to ciprofloxacin has been isolated in a patient with severe pneumonia 
(42). A recent meta-analysis comparing quinolones with macrolides suggested that 
patients receiving quinolones had a lower morality rate and shorter hospital stay (43).
2.5 Epidemiology
The exact incidence of LD is unknown. Most of the available epidemiological infor-
mation on LD comes from surveillance data or outbreak investigations. It is esti-
mated that approximately 5% of community-acquired pneumonia could be caused by 
Legionella (44). This proportion could even be higher in Europe. A European study 
looking at the impact of infectious diseases on population health using incidence-
based disability-adjusted life years (DALYs) found that LD had the fifth highest 
burden after influenza, tuberculosis, human immunodeficiency virus (HIV) infec-
tion/AIDS and invasive pneumococcal disease (45) (Figure 2). Almost all DALYs 
associated with LD were due to years of life lost due to premature mortality (YLL).
Figure 2. Median annual DALYs per 100,000 population for selected infectious diseases, 
EU/EEA countries, 2009–2013. Source: Cassini, A. 2018 (45) 
6EU/EEA: European Union/European Economic Area; HAV: Hepatitis A virus; 
HBV: Hepatitis B virus; HIV/AIDS: Human immunodeficiency virus infection; 
IHID: Invasive Haemophilus influenzae disease; IMD: Invasive meningococcal 
disease; IPD: Invasive pneumococcal disease; STEC/VTEC: Shiga toxin/verocy-
totoxin-producing Escherichia coli; TBE: Tick-borne encephalitis; vCJD: variant 
Creutzfeldt–Jakob disease; YLD: years lived with disability; YLL: years of life lost 
due to premature mortality. The error bars indicate the 95% uncertainty intervals.
Over the 2011–15 period, the age-standardized rate (ASR) of LD ranged 0.01 
cases per 100,000 population in Bulgaria and Romania to 3.46 cases per 100,000 
population in Slovenia (5). Most central and eastern European countries had ASR 
below 0.5 cases per 100,000 population (Figure 3). 
Figure 3. Age-standardized rate of Legionnaires’ disease per 100,000 population by coun-
try, European Union/European Economic Area, 2011–2015. Source: Beauté, J. 2017 (5)
The overall notification rate for the EU/EEA continued to increase in the following 
years from 1.3 per 100 000 population in 2015 to 1.8 per 100 000 population in 
2017 (46). The most recent data available suggest that the increase continued in 
2018 (Figure 4). Comparable rates were reported in the USA (10, 47). However, 
a recent study based on hospitalization data carried out in Connecticut, USA sug-
gested a substantial underdiagnosis with an estimated rate above 10 cases per 
100 000 population (48).
72.5.1 Demographics
Globally, demographics are quite similar across countries (7). The disease is rare in 
children and most cases occur in adults with a median age at date of onset between 
60 and 65 years. Notifications rates increase with age and approximately 80% of 
reported cases occurred in people older than 50 years. LD is more common in 
males and the male-to-female ratio is approximately 2.5:1 (37).
2.5.2 Risk factors
Known risk factors for LD include increasing age, male sex, smoking, chronic lung 
disease, diabetes, and various conditions associated with immunodeficiency (49, 
50). A recent population-based study carried out in the USA identified 12 clinical 
conditions associated with an increased risk of LD (51). In addition to previously 
known risk factors such as chronic lung disease, this study suggested that other 
clinical factors could play a role, including cardiovascular disease and neurological 
disease. that In addition, poverty and certain occupations may also be associated 
with a higher risk for LD (52). Thus, in a study carried out in the United States, 
working in transportation, repair, protective services, cleaning, or construction 
was associated with a higher risk for community-acquired LD.
2.5.3 Seasonality
In North America and in Europe, the monthly distribution of LD cases shows a 
clearly seasonality with most cases reported during the warm season (10, 37). For 
example, in 2015 approximately 60% of all cases reported in Europe had a date 
Figure 4. Distribution of Legionnaires’ disease cases by month, EU/EEA, 2014–2018 
Source: Country reports from Austria, Belgium, Bulgaria, the Czech Republic, Cyprus, 
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, 
Slovakia, Slovenia, Spain, Sweden and the United Kingdom.
8of onset between June and October (7). In the USA the seasonality seemed to 
be less pronounced in states with mild climates (south and west census regions) 
(Figure 5). Data from Japan, South Korea and Taiwan suggested a similar pattern 
in other parts of the world (53, 54).
Figure 5. Annual average percentage of legionellosis cases occurring annually, by month 
and U.S. Census region* – United States, 2000–2009. Source: Centers for Disease Control 
Prevention (10)
* Northeast: Connecticut, Maine, Massachusetts, Rhode Island, Vermont, New Jersey, 
New York, and Pennsylvania; Midwest: Indiana, Illinois, Michigan, Ohio, Iowa, Nebraska, 
Kansas, North Dakota, Minnesota, and Missouri; South: Delaware, District of Columbia, 
Florida, South Carolina, West Virginia, Kentucky, Louisiana, Oklahoma, and Texas; West: 
Colorado, Idaho, New Mexico, Montana, Utah, Nevada, Wyoming, Alaska, California, 
Hawaii, Oregon, and Washington.
2.5.4 Outcome
In Europe, the case fatality is approximately 10% but is usually higher in older 
age groups (5). When adjusting for age and sex, healthcare-associated cases were 
significantly associated with a higher risk for fatal outcome compared to other 
settings of infection. A study in France suggested that female sex, age, admission 
to ICU, renal failure, corticosteroid treatment and increased level of C-reactive 
protein (CRP) were associated with a higher mortality (55).
92.5.5 Outbreaks
LD was first described after an outbreak during a convention of the American 
Legion in 1976 (2). Although the source of the outbreak could never be confirmed 
(visiting the hotel lobby was a risk factor), the epidemiological curve is still pre-
sented in textbooks as a typical example of a point-source outbreak (56).
In Europe, the vast majority of cases is thought to be sporadic (>90%) (5). However, 
in the absence of sound cluster definition for most settings of infection, it is difficult 
to estimate the exact proportion of cases associated with the same probable source 
of infection. Clusters of travel-associated cases and healthcare-associated cases 
are probably easier to identify although the source of infection is seldom identi-
fied. Large outbreaks may be associated with specific morbidity. Thus, impaired 
health-related quality of life and posttraumatic stress disorder have been reported 
among survivors of LD outbreaks (57). Outbreaks attract a lot of media attention 
and can trigger changes in health policy (58).
During LD outbreaks, the localization and removal of the source of infection is 
essential to prevent further cases. In some outbreaks, the probable source of infec-
tion is easily identified because most cases stayed or visited in the same location. 
In large outbreaks, cooling towers are often identified as the source of infection 
(Table 1). 
Table 1. Selection of large outbreaks of LD (>100 cases), 1976–2018. Adapted from 
Phin (2014) (7)
Place Year Number 
of cases
Case 
fatality
Source Ref.
Philadelphia, USA 1976 182 16% Not confirmed (2)
Los Angeles, USA 1977–82 >200 - Potable water (59)
Bovenkaspel, Netherlands 1999 188 11% Whirlpool spa (31)
Melbourne, Australia 2000 125 3% Cooling tower (60)
Murcia, Spain 2001 449 1% Cooling tower (8)
Barrow-in-Furness, UK 2002 197 4% Cooling tower (61)
Miyazaki, Japan 2002 295* 2% Public bathhouse (62)
Sarpsborg, Norway 2005 103 10% Industrial air scrubber (63)
Pamplona, Spain 2006 146 0% Cooling tower (64)
Quebec, Canada 2012 182 8% Cooling tower (65)
Vila Franca de Xira, Portugal 2014 334 4% Cooling tower (9)
New York, USA 2015 138 12% Cooling tower (66)
* including suspected cases.
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However, the source of an outbreak, especially a community outbreak, remains 
sometimes undetected. Classical approaches for outbreak investigation (case-
control studies) are often unfruitful. The analysis usually focuses on the inter-
action of cases with their environment. Although the place of residence is easily 
obtained, the collection of detailed data on case movements during the potential 
exposure period can be challenging. In such cases, the investigation can benefit 
from other tools such as geographic information systems (GIS) (67). GIS are 
tools that collect, analyze and display data with any geographical component. The 
use of GIS during an LD outbreak may help identify spatial patterns in relation 
with a common source of infection (Figure 6). The analysis can include not only 
case data but also potential sources locations (e.g. cooling towers), demographic 
data, and meteorological data. Thus, there are example of successful investiga-
tions that identified the source by simulating the dispersion of aerosols emitted 
from a number of potential sources of infection (68). If basic spatial information 
for cases is usually easily retrieved (home location, place of work, places visited 
etc.), the collection of detailed travel routes or places of shorter stay during the 
potential exposure period can be very challenging with traditional questionnaire 
techniques. Data of subscriber identity module (SIM) cards from mobile phones 
have recently be used with success during a cholera outbreak to track population 
movements (69). A similar methodology could yield promising results in LD 
outbreak investigation. 
Figure 6. Crude attack rates of Legionnaires’ disease by census tract and cooling towers 
testing positive for Legionella pneumophila serogroup 1 (Lp1), Bronx, New York City, July 
2 to August 3, 2015. Source: Weiss (2017) (71)
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Whole-genome sequencing (WGS) is increasing used in outbreak investigation. 
Theoretically, WGS could help matching isolates from clinical and environmental 
samples but often only highlight a wide genetic diversity across clinical and water 
isolates (70). LD outbreaks may be associated with multiple LD strains.
2.5.6 Setting of infection
For surveillance purposes, LD cases are usually classified by probable setting of 
infection. These settings are associated with some specific characteristics.
2.5.6.1 Community-acquired cases
Most LD cases are community-acquired cases and sporadic. In Europe, approxi-
mately 70% of all cases reported in the recent years were community-acquired, of 
which 5% were reported as part of a cluster. Countries are asked to report cases as 
having formed part of a cluster if one case was exposed to the same source as at 
least one other case with their dates of onset within a plausible time period (37).
2.5.6.2 Travel-associated cases
In Europe, cases are reported as travel-associated if they stayed at an accommo-
dation site away from home during their incubation period. Cases who stayed in 
accommodation used for commercial purposes (such as hotels) should also be 
reported in dedicated surveillance scheme (see below).
Overall, approximately 20% of European LD cases are travel-associated (TALD), 
of which half travelled in their country of residence (37). TALD tend to be younger, 
especially those with a travel history abroad and have a lower case fatality. A study 
using European data estimated the overall risk associated with travel abroad at 
0.3 cases/million nights. An increasing trend in risk from north-western to south-
eastern Europe was observed with Greece having the highest risk (1.7 cases/million 
nights) (72). 
Although TALD cases are more frequently associated with stays in hotels (73), 
Legionella in the water system was detected more frequently in ferries than in 
hotels (74). In hotels, cooling towers and/or potable water systems were the most 
frequent incriminated source while hot tubs were most commonly associated with 
cases occurring in ships.
A study suggested that the probability of successive LD cases to occur in European 
hotels depended on the country and the size of the hotel (75). The size of the hotel 
was also associated with reoffending accommodation, i.e. associated with further 
LD cases after a first investigation following a cluster notification (76). 
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2.5.6.3 Healthcare-associated cases
Legionnaires’ disease is known to be a significant cause of nosocomial pneumonia 
leading to important costs both in treatment and prevention (77). In addition to 
inhalation, aspiration is thought to be another mode of transmission of HCA LD 
(78). Studies have suggested that a substantial proportion of hospitals may have 
their water systems colonized by Legionella but the percent positivity that should 
prompt action remains controversial (79). More worrying, studies performed in 
the USA suggested that most HCA LD cases were linked to contamination of the 
potable water systems (80). Hospitalized people are at higher risk for LD because 
they tend to be older and more likely to have chronic disease compare to the 
general population. Therefore, outbreaks of LD in hospitals are not uncommon 
(81). Indeed, a review of LD outbreaks suggested that approximately 25% of LD 
outbreaks occurred in healthcare settings (82).
Since nosocomial infection is more likely to occur in immunocompromised  people, 
a higher proportion of non-L. pneumophila serogroup 1 would be expected. Thus, 
it has been shown that less than 50% of nosocomial cases can be diagnosed by 
urinary antigen detection (83). Case fatality is usually higher in nosocomial cases 
(≈30%) (37).
It is likely that healthcare-associated cases are both poorly diagnosed and reported 
throughout Europe. Of the 470 healthcare-associated cases reported in 2015, 343 
(73%) were reported by France, Italy and Spain (37). 
2.6 Surveillance
2.6.1 The European Legionnaires’ disease Surveillance Network
Since 2010, the surveillance of LD in Europe has been carried out by the European 
Legionnaires’ Disease Surveillance Network (ELDSNet) and coordinated by the 
European Centre for Disease Prevention and Control (ECDC). ELDSNet involves 
28 EU Member States, Iceland and Norway (37). 
It is mandatory to notify all cases of Legionnaires’ disease in Europe. All cases meet-
ing the EU case definition for LD should be reported to the European Surveillance 
System (TESSy), a database hosted by ECDC. According to the type of laboratory 
test used to ascertain the case, cases are classified as confirmed or probable (84).
LD is thought to be underreported for two main reasons. Firstly, it is underdiagnosed 
by clinicians. Especially when treating milder forms of chest infection, patients 
are not tested for LD before empirically prescribing broad-spectrum antibiotics 
that are likely to cover Legionella spp. Secondly, health professionals may fail 
to notify cases to health authorities due to the added administrative burden (1).
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2.6.2 Indicator-based surveillance
Indicator-based surveillance refers to the collection of structured data relying on 
established routine surveillance systems. It is usually opposed to ‘Event-based 
surveillance’ in which unstructured data are collected through the screening of 
various sources (85). LD surveillance is indicator-based and relies on two  different 
schemes: one covering all cases (comprehensive notifications) reported from 
European Union (EU) Member States, Iceland and Norway, the other covering all 
travel-associated cases of Legionnaires’ disease (TALD), including reports from 
countries outside the EU/EEA. 
The aims of these two schemes differ. The main objectives of collecting data on 
all nationally reported cases of LD are: 
• to monitor trends over time and to compare them across Member States; 
• to provide evidence-based data for public health decisions and actions at EU 
and/or Member State level; 
• to monitor and evaluate prevention and control programs targeting LD at 
national and European level; 
• to identify population groups at risk and in need of targeted preventive measures 
(37).
The surveillance of TALD aims primarily at identifying clusters of cases that may 
not otherwise have been detected at the national level, and enabling timely inves-
tigation and control measures at the implicated accommodation sites in order to 
prevent further infections.
2.6.2.1 Comprehensive notifications
Each year, all EU/EEA countries are invited to submit the LD data of the previous 
year to ECDC. All LD cases meeting the European case definition are included 
(Box) (84). This case definition was amended in August 2012 and it is no longer 
possible to report probable cases with an epidemiological link only.
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European Union case definition for  
Legionnaires’ disease
Clinical criteria:
Any person with pneumonia.
Laboratory criteria for case confirmation:
At least one of the following three:
• Isolation of Legionella spp. from respiratory secretions or any 
normally sterile site;
• Detection of Legionella pneumophila antigen in urine;
• Significant rise in specific antibody level to Legionella 
 pneumophila serogroup 1 in paired serum samples.
Laboratory criteria for a probable case:
At least one of the following four:
• Detection of Legionella pneumophila antigen in respiratory  
secretions or lung tissue e.g. by DFA staining using  
monoclonal-antibody-derived reagents;
• Detection of Legionella spp. nucleic acid in respiratory  
secretions, lung tissue or any normally sterile site;
• Significant rise in specific antibody level to Legionella 
 pneumophila other than serogroup 1 or other Legionella  
spp. in paired serum samples;
• Single high level of specific antibody to Legionella  
pneumophila serogroup 1 in serum.
Case classification
Probable case
Any person meeting the clinical criteria AND at least one 
 positive laboratory test for a probable case.
Confirmed case
Any person meeting the clinical AND the laboratory criteria 
for case confirmation.
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2.6.2.2 Travel-associated Legionnaires’ disease
A travel-associated Legionnaires’ disease (TALD) surveillance system at the 
European Union (EU) level has been in place since 1987 (86). Since 2010, ELDSNet 
members report TALD cases to ECDC on a daily basis through the web-based 
European Surveillance System (TESSy). TALD cases need to fulfil the official EU 
case definition for LD and to have a history of travel, i.e. at least one night spent in 
commercial accommodation away from home within the incubation period of LD. 
ELDSNet defines a cluster of TALD as two or more cases who stayed at or visited 
the same commercial accommodation site in the two to ten days before onset of 
illness and whose onset is within the same two-year period. Interestingly, a study 
challenged the current definition for TALD cluster suggesting that a more  flexible 
definition would allow the detection of more sites (87). In addition, ELDSNet 
defines a rapidly evolving cluster as at least three cases with dates of onset within 
a three-month period. The detection of a cluster in the Member States will prompt 
action in the accommodation and follow-up by health authorities of the measures 
taken. No action is required for accommodations associated with single cases. 
When ELDSNet detects a cluster, an investigation by public health authorities 
is required at the accommodation site. To be able to effectively prevent further 
cases, all notifications done through this scheme should be timely, i.e. shortly after 
occurrence of a case. In 2016, the median time from date of onset to reporting to 
ELDSNet was 19 days (range 6–47 days). ELDSNet subsequently notified the 
country where the accommodation site associated with the TALD cases was located 
within days (mostly the same or following day of reporting to ELDSNet) (88). 
2.7 Prevention and control
LD is a preventable disease and key to prevent LD is to ensure the proper mainte-
nance of water systems. The plan for water risk management developed by the World 
health Organization (WHO) provides a framework applicable to Legionella-related 
issues (16). This so-called water safety plan (WSP) consist of three main compo-
nents: (a) system assessment; (b) monitoring; (c) management and communication.
There are several existing regulations and guidelines for Legionella control. Most 
of them share three common principles (89). First, they highlight the importance 
of avoiding and monitoring spots that favor the growth of Legionella. Second, 
they propose measures to limit water stagnation, which is propitious to Legionella 
proliferation. Last, they require sufficiently high temperature to prevent the growth 
of Legionella. For instance, there is evidence suggesting that hot water temperature 
and frequent running showers could reduce Legionella contamination of domestic 
household (90).
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Unfortunately, it seems that many LD outbreaks could be associated with deficien-
cies in environmental control as suggested by a study carried out in the USA (91).
2.8 Research priorities
Among the main research priorities identified by Phin et al., there are several 
aspects that are worth mentioning, including LD epidemiology, outbreak investi-
gation, diagnostics tests, and ecology (7). 
2.8.1 Epidemiology
First, in the absence of reliable estimates of the disease incidence, it is difficult to 
evaluate the real burden of LD, in Europe and in the rest of the World. Therefore, 
it is important to provide better estimates of LD incidence and to quantify associ-
ated morbidity and mortality. Since LD remains a relatively rare disease, a better 
understanding of host factors (e.g. genetic or immunologic) associated with a higher 
susceptibility to Legionella would help target people at higher risk of infection. 
This thesis investigates LD epidemiology in two specific settings, travel (Study I) 
and healthcare (Study IV). Study I paid extra attention to the somehow neglected 
LD associated with domestic travel. 
2.8.2 Outbreak investigation
Recent years have seen an increasing use of new tools in outbreak investigation. 
For LD outbreaks, GIS tools could be promising.
Study III took advantage of the data generated by the longtime functioning scheme 
of TALD surveillance in Europe, in which information on control measures are 
systematically collected.
2.8.3 Diagnostic tests
The accuracy of LD diagnostic tests should be improved. The landscape of LD 
diagnostic tests is currently dominated by UAT with their limitations, especially 
the incapacity to detect species other than L. pneumophila serogroup 1. The 
increasing use of PCR may change this landscape if standardized methods are 
defined and applied. 
Focusing on LD cases in healthcare settings, Study IV explored various LD strains 
and the characteristics of the cases that they caused. 
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2.8.4 Ecology
To better control and potentially eradicate Legionella from water systems, a better 
understanding of its ecology is needed. Risk associated with certain concentrations 
in different setting should be better estimated. The development of environ mental 
surveillance could help map the risk of LD. This would be helped by a better 
understanding of the environmental drivers of LD.
Using data from four European countries at subnational level, Study II tried to 
quantify the role of several environmental drivers on the incidence of community-
acquired LD cases.
Study III used the information collected in the near-real-time surveillance of TALD, 
which include the results of environmental investigation following the detection 
of a cluster of TALD cases.
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3 AIMS
The overarching aim of this thesis was to explore various aspects of LD epidemi-
ology, prevention and control using surveillance data.
The specific aims of the studies are as follows:
Study I: To assess the risks for TALD in European countries on the basis of 
travel patterns and to provide an estimate of the extent of under-ascertainment by 
 country of destination;
Study II: To test and investigate the effect of temperature, rainfall, and atmos-
pheric pressure on short-term variations in LD notification rate;
Study III: To identify factors associated with the occurrence of further cases 
after implementation of control measures to improve prevention and control of 
LD in travelers.
Study IV: To describe the epidemiology of HCA LD using EU-level surveillance 
data and to determine how it differs from the epidemiology of community-acquired 
LD in terms of seasonality, demographics, causative pathogens and outcome.
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4 DATA
4.1 Legionnaires’ disease data
In both Studies II and IV we used LD surveillance data collected through the 
annual scheme (cf. 2.6.2.1). Each year, EU/EEA countries report all LD cases 
meeting the EU case definition to ECDC. Although most surveillance systems are 
similar, there are some differences across countries (92). With the exception of 
Belgium, all countries had surveillance systems with national coverage. Through 
this scheme, some of the variables collected are common to most diseases under 
EU/EEA surveillance. This set of basic epidemiological variables includes age, 
sex, date of onset, date of diagnosis, place of residence, and outcome. In addition 
to these basic variables, there are some disease-specific epidemiological variables, 
which include laboratory method, importation status, probable country of infection, 
cluster status, pathogen information (LD strain, monoclonal subtype, and sequence 
type), probable setting of infection, and results of possible environmental inves-
tigations. Data completeness is high for most basic variables (>90%). However, 
completeness was poor for some disease-specific variables. For example, less 
than 5% of reported cases had information on the sequence type of the causative 
strain during 2010–2015 (37).
In Study II we extracted a subset of these data, including all community-acquired 
LD cases reported by Denmark, Germany, Italy, and The Netherlands with onset 
date in 2007–2012. We aggregated cases by onset week and region of residence 
(NUTS 2). Community-acquired is a diagnosis of exclusion. A case is community-
acquired if there is no history of travel or admission to a hospital in the 2 to 10 
days prior to disease onset.
In Study IV we included all locally-acquired cases reported during the years from 
2008 to 2017. We defined a locally-acquired case as any case not reported as 
travel-associated. We used the following variables for the analysis: age, sex, date 
of disease onset, probable setting of infection, cluster status, laboratory method 
used for diagnosis, pathogen and clinical outcome (dead or alive).
4.2 Travel-associated Legionnaires’ disease data
The variables collected through the near-real-time surveillance scheme of TALD 
are very similar to those collected for comprehensive notifications. In addition, 
this scheme collects information on travel history. Travel history includes accom-
modation type (e.g. hotel), arrival and departure dates, and the location of the 
accommodation.
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Study I was based on TALD surveillance data. We aggregated TALD cases by 
reporting country and destination country for the year 2009. We restricted the 
analysis to European residents travelling in EU/EEA countries. The use of surveil-
lance data is considered a valid source to estimate risk in travelers (93).
4.3 Epidemic Intelligence Information System data
The Epidemic Intelligence Information System for ELDSNet (EPIS-ELDSNet) 
is a web-based communication platform used by nominated public health experts 
to detect and follow-up travel-associated clusters of LD. ECDC staff investigates 
TALD data on a daily basis and identifies cluster of TALD (cf. 2.5.6.2). Notification 
of cluster to the member states and follow-up of control measures are both carried 
out in the EPIS-ELDSNet platform.
For Study III we used EPIS-ELDSNet data and included all hotel and holiday 
rental accommodation sites in the EU/EEA that were associated with a cluster of 
TALD cases notified between 1 June 2011 and 31 December 2016. 
4.4 Tourism denominator data
For Study I, travel denominator data were obtained from the Statistical Office of 
the European Union (Eurostat) (94). We used the total number of nights spent, by 
destination country. This includes all nights spent in a collective accommodation 
establishment or in private tourist accommodation for personal or professional 
purposes by EU/EEA residents, aged 15 or older. Most countries collected such 
information through household surveys. To ensure maximum data quality countries 
are required to follow the instructions described in the Methodological manual 
for tourism statistics (95). 
4.5 Meteorological data
For Study II, meteorological data were extracted from the European Climate 
Assessment & Dataset project (ECA&D). ECA provides access to  homogenized 
high-quality datasets based on daily station series maintained by national meteoro-
logical institutes. Previous studies have demonstrated the quality of ECA datasets 
(96). For the purpose of study II, meteorological variables of interest were aggregated 
by week at regional level (NUTS2) for the period 1 January 2007−31 December 
2012 (Figure 7).
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4.6 Accommodation size data
In Study III, we looked at the risk of occurrence of a further TALD case after 
implementation of control measures in accommodation sites. Since this risk is 
likely to be associated with the number of guests visiting the accommodation, it 
was necessary to control for this. Information on the annual number of guests was 
unfortunately not available. Therefore, we decided to use the number of rooms 
as a proxy. Since surveillance data did not capture this information, we searched 
the number of rooms for each accommodation in two of the most popular travel 
website companies (Booking.com and TripAdvisor). This was a tedious work with 
manual investigation of nearly 400 accommodation sites. 
4.7 Ethical considerations
All studies relied on surveillance data routinely collected by ECDC. These data 
are submitted by EU/EEA Member States in compliance with the EU regula-
tions, especially Decision 1082/2013 and its Implementing Decision (84). LD is 
part of the 56 communicable diseases for which ECDC coordinates surveillance 
Figure 7. Weekly average temperature, cumulative rainfall, average atmospheric pressure 
and number of Legionnaires’ disease cases at NUTS2 level, Denmark, Germany, Italy, and 
the Netherlands, 2007−2012
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 activities as stated by the Article 3 of its founding regulation. These surveillance 
data are anonymized and processed for public interest in the area of public health. 
Therefore, informed consent was not required or subject to national policies. Yet, 
most of these data are case-based and contain personal information.
Both Study I and II were based on aggregate subset of LD surveillance data. For 
Study I, data were aggregated at national level, by destination country for the 
year 2009. For study II, data were aggregated by week of onset at regional level 
(NUTS2). Aggregate data do not fall under the law of ethical review for research 
in Sweden.
Study III was based on accommodation data. Since it was not possible to identify 
any of the accommodations included on the analysis, there was no risk of under-
mining commercial interests.
Data used for study IV were anonymized. This means that no individual could be 
identified. The variables used for the purpose of this analysis were age, sex, date 
of disease onset, probable setting of infection, cluster status, laboratory method 
used for diagnosis, pathogen and clinical outcome (dead or alive). 
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5 STATISTICAL METHODS
5.1 Poisson regression
Study II aimed to estimate the association between meteorological variables and 
the weekly number of community-acquired LD cases. The outcome measure was 
the weekly number of cases for each geographical area (NUTS2 region) given its 
population (included as an offset). Poisson regression is a method used to analyze 
rates or counts of rare events (97). It allows the comparison of different exposure 
groups, estimating and controlling for effects that change over time. We used 
Poisson regression to estimate relative risks (RR) from rate ratios and their 95% 
confidence intervals (CI). 
Since the median incubation duration for LD is approximately one week, we 
assumed that a time lag of one week between exposure to weather conditions and 
disease onset to be the most likely. Yet, the weather conditions observed in pre-
vious weeks could also play a role. Therefore, we allowed for delayed exposure 
effects up to four weeks before date of onset. To compare the goodness-of-fit of our 
models, we used Akaike’s Information Criterion (AIC) (98). We selected models 
with the lowest AIC because they are thought to minimize the information loss. 
The three exposure variables considered (cumulative rainfall, mean temperature 
and mean atmospheric pressure) might share some collinearity. For example, low 
atmospheric pressure is likely to be associated with rainfall. to address potential 
problems related to multicollinearity between continuous covariates, we calcu-
lated the variance inflation factor (VIF) (99). VIF is an indicator quantifying the 
severity of multicollinearity. If there is collinearity among the variables, VIF is 
expected to increase sharply.
5.2 Modelling seasonality and long-term trends
Since LD incidence is known to have a pronounced seasonality, it is necessary to 
control for the seasonal patterns in the regression model. Otherwise, it would not 
be possible to distinguish the seasonal patterns from the short-term associations 
between weather conditions and LD incidence (Study II). Bhaskaran et al. proposed 
three alternative for modelling seasonal and long-term patterns (100) (Figure 8): 
a) The first and simplest approach is to split the study period into short intervals 
and to include an indicator variable for each interval in the model (time-
stratified model). We discredited this approach because it would have generated 
too many parameters. In addition, the differences observed between two 
adjacent intervals may be difficult to interpret.
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b) The second approach is to model long-term patterns by fitting Fourier terms in 
the model. Although such cyclic regression would model smoothly seasonality, 
we rejected it because it would force the timing of each peak to be identical 
for each cycle.
c) The third option proposed by Bhaskaran is to fit a spline function of time. Spline 
functions are polynomial functions joined by knots. This was our preferred 
option because spline functions allow seasonal patterns to change over time 
and can also capture non-seasonal long-term trends. The only drawback is their 
mathematical complexity. For the purpose of study II, we selected restricted 
cubic spline functions with 3 degrees of freedom (DF) for knots and the spline 
basis centered on the median value of the exposure (default setting in Stata).
Figure 8. Three alternative ways of modelling long-term patterns in the data (seasonality 
and trends). Source: Bhaskaran (2013) (100)
25
5.3 Survival analysis
In Study III we examined the occurrence of further LD cases after implementation 
of control measures in accommodation sites associated with a cluster of TALD. 
The outcome of interest was the time to a further LD case. Survival analysis deals 
with time-to-event outcomes. In survival analysis there is no need to assume that 
the risk of occurrence of the event is constant over time. In our study, it would 
be reasonable to assume that the risk of occurrence of a further LD case may be 
lower immediately after implementation of control measures but could increase 
later on if the measures effects wane over time. 
Survival analysis relies on a survivor function S(t) and a hazard function h(t). 
The hazard function represents the instantaneous rate at time t. In Study III, h(t) 
corresponds to the rate of occurrence of further cases after the report on control 
measure (number of cases per 100 accommodation-years). The survival function 
is the probability that an accommodation will not experience the event of interest 
(i.e. occurrence of a further case) up to and including time. Since the exact  failure 
time is known (date of occurrence of a further case) it is possible to estimate the 
exact failure and censoring times by the Kaplan-Meier estimate (97). In study III 
we reported cumulative incidence of accommodations sites associated with a 
 further TALD case (i.e. inverse of survival function using Kaplan-Meier estimate) 
and compared different groups using the log-rank test. Accommodations sites for 
which no further LD cases was reported were censored on 31 December 2016, 
which was the end of the study period (right censoring).
To quantify the differences in survival across groups, we fitted Cox proportional 
hazards models. The Cox regression has several advantages, one that the baseline 
risk (“hazard”) does not have to be modeled explicitly. Instead, the Cox models 
assuming that the ratio of the hazards between the groups of interest is constant 
over time. There are various methods to assess the validity of this assumption, 
including plotting Schoenfeld residuals (101).
5.4 Logistic regression
In Study IV, we compared binary outcomes (e.g. dead or alive) between two 
exposure groups, which were two probable settings of infection (community or 
healthcare). For such analysis, logistic regression is a commonly used method (97). 
Logistic regression models the association between exposure and binary outcome 
variables in terms of odds ratio (OR). It is then possible to derive confidence inter-
vals (CI) by using the standard error of the log OR to calculate a CI for the log OR. 
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In study IV, we fitted two main models. The first one estimated the OR of HCA LD 
compared to community-acquired LD. The second estimated the OR of fatal LD 
compared to non-fatal LD. For both models, we included a small number of vari-
ables (first model: age, sex, reporting year, and reporting country; second model: 
age, sex, reporting year, reporting country, and probable setting of infection). 
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6 MAIN RESULTS
6.1 Risk for travel-associated Legionnaires’ disease 
(Study I)
Of the 607 TALD cases reported among European residents travelling in EU/EEA 
countries in 2009, 363 (60%) were related to domestic travel, i.e. travel in their country 
of residence. The top three travel destinations (France, Italy, and Spain) accounted 
for 72% of all TALD cases. TALD cases were associated with stays in hotels (70%), 
campsites (8%), private accommodations rented for commercial purposes (6%), 
apartments (5%), cruise ships (<1%), and other accommodations (10%). In 2009, 
EU/EEA residents spent two billions nights in Europe, of which 66% were in their 
country of residence. France, Italy, and Spain accounted for 46% of all nights spent. 
In 2009, the average risk for TALD in Europe in 2009 was 0.30 cases/1 million 
nights (95% CI 0.27–0.32). The highest for domestic travel was in Italy (0.66 
cases/1  million nights) and for non-domestic travelers in Greece (0.88 cases/1 mil-
lion nights). Using the best reporting countries as reference (the UK, the Netherlands, 
France, and Denmark), we estimated a pooled overall risk of 0.55 cases/million 
nights and a pooled risk of 1.68 cases/1 million nights when traveling to Greece 
(Table 2). We observed the highest level of under-ascertainment in Greece, Portugal, 
and Austria (Germany did not report cases in domestic travelers until 2012.
Table 2. Expected risk for Legionnaires’ disease in European travelers to non-
domestic destinations in Europe, based on reference data reported by the 
United Kingdom, the Netherlands, France, and Denmark, Europe, 2009
Destination Risk in travellers 
(cases/million nights)
Incidence ratio 
(95% conf. interval)
Total cases (n)
Reported Estimated
Greece 1.68 7.2 (4.2-12.2) 34 98
Italy 1.40 6.0 (3.9-9.2) 209 463
Germany 1.19 5.1 (2.9-8.7) 22 353
Portugal 1.06 4.6 (2.1-9.0) 20 44
Austria 1.01 4.4 (2.2-8.2) 20 95
Spain 0.57 2.5 (1.6-3.8) 98 188
France 0.53 2.3 (1.6-3.3) 137 145
Netherlands 0.33 1.4 (0.8-2.4) 21 26
UK 0.23 1.0 (ref.) 45 53
Other countries 0.90 3.9 (2.3-6.4) 42 282
Total 0.55 - 607* 1 127
* A case may have a travel history involving more than one country
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6.2 Short-term effects of meterological conditions on 
incidence of Legionnaires’ disease (Study II)
Four countries (Denmark, Germany, Italy and the Netherlands) accepted to par-
ticipate in the study by providing data at regional level (NUTS2). This represented 
77 NUTS regions with a corresponding population of 164 million inhabitants. 
Of the 8,708 LD cases reported during 2007−2012, 8,093 (93%) had available 
information on both onset date and place of residence. We excluded cases with 
onset in the first four weeks of 2007 for which we had no or partial exposure data 
(the time series for meteorological data started on 1 January 2007). Finally, we 
included 7,961 cases in the analysis.
We found a positive association between weekly cumulative rainfall and an 
increased risk of LD. We observed the association with the highest risk and the 
lowest AIC with a lagged effect of 1 week (RR 1.13 for every 10-mm increase, 
95% CI 1.12–1.14). We found a positive association between weekly mean tem-
perature and an increased risk of LD. We observed the association with the highest 
risk and the lowest AIC with a lagged effect of 3 weeks (RR 1.05 for every 2°C 
increase, 95% CI 1.03–1.07). 
We kept in the adjusted model meteorological variables with the lag associated 
with the highest RR and lowest AIC. There was no indication of multicollinear-
ity between these variables according to calculated VIC (<10). With no weekly 
rainfall as a reference, the estimated adjusted RR of LD for weekly cumulative 
rainfall >40 mm with a lagged effect of 1 week was 2.14 (95% CI 1.90–2.42; rate 
182 vs. 62 LD cases/10 million population). With weekly mean temperature <10°C 
as a reference, the estimated adjusted RR of LD for weekly mean temperature of 
15–19°C with a lagged effect of 3 weeks was 2.00 (95% CI 1.75–2.28, rate 120 
vs. 54/10 million population). Interestingly, the effect of temperature plateaued 
above 20°C.
We found positive interactions between increasing weekly cumulative rainfall 
(1 week lag) and increasing weekly mean temperature (3 weeks lag) (Table 3). 
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Table 3. Estimated relative* risk and 95% CI of community-acquired Legionnaires’ 
disease for an interaction between weekly cumulative rainfall (one week lag) and 
weekly mean temperature (three weeks lag), Denmark, Germany, Italy and the 
Netherlands, 2007−2012
Weekly 
 cumulative 
rainfall (one 
week lag)
Weekly mean temperature (three weeks lag)
<10°C 10 to 14°C 15 to 19°C ≥20°C
<10 mm 1 (ref.) 1.20 (1.04-1.37) 1.66 (1.42-1.95) 1.50 (1.24-1.81)
10 to 19 mm 1.13 (1.01-1.28) 1.53 (1.31-1.79) 2.00 (1.69-2.37) 1.70 (1.38-2.11)
20 to 29 mm 1.31 (1.15-1.50) 1.82 (1.54-2.17) 2.77 (2.34-3.27) 2.66 (2.14-3.32)
≥30 mm 1.37 (1.21-1.55) 2.28 (2.00-2.61) 3.50 (3.00-4.08) 2.90 (2.38-3.54)
* Relative risks from Poisson regression including covariates year (2007−2012), NUTS2 (one 
intercept for each region), population, weekly cumulative rainfall (one week lag), weekly mean 
temperature (three weeks lag), weekly mean atmospheric pressure (one week lag), adjusted for 
season using a cubic spline function with five knots, and an interaction term.
We found the highest RR for weekly mean temperature of 15–19 °C and cumulative 
rainfall >30 mm compared to temperature <10 °C and rainfall <10 mm (RR 3.50, 
95% CI 3.00–4.08). 
6.3 Factors associated with Legionnaires’ disease 
recurrence in hotels (Study III)
During 1 June 2011−31 December 2016, 395 accommodation sites in the EU/EEA 
were notified with a cluster of TALD cases. Of these, 357 (90%) had informa-
tion on both follow-up of control measures and number of rooms. Of these 357 
accommodations, 90 (25%) were associated with at least one further case after the 
report on measures taken (12.4/100 accommodation-years). We observed higher 
cumulative incidences for accommodation sites associated with a previous case 
compared with those that were never associated with any case before the cluster 
(Figure 9). After 3 years of follow-up, 50% of the accommodations previously 
reported with two cases or more were associated with a further case.
Accommodation sites with 36 rooms or more had a higher risk of a further case 
compared to those with less than 36 rooms (HR>2). Accommodations previously 
associated with two cases or more had a HR of 2.26 (95%CI: 1.40–3.64). We 
found no association between the detection of Legionella in the water system nor 
the type of disinfection and the risk of a further case. 
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6.4 Healthcare-associated Legionnaires’ disease 
(Study IV)
Over the 2008−2017 period, 30 countries reported 64,409 LD cases, of which 57,175 
(88.8%) had the information available for inclusion. Of these, 40,411 (70.7%) 
were reported as community-acquired, 11,512 (20.1%) as travel-associated, 4,315 
(7.6%) as healthcare-related and 937 (1.6%) as associated with other settings. 
Finally, we included 44,726 LD cases in the analysis reported by 29 countries, of 
which 40,411 (90.4%) were community-acquired and 4,315 (9.6%) HCA LD. Of 
the 4,315 HCA LD cases, 2,937 (68.1%) were nosocomial cases and 1,378 (31.9%) 
linked to other healthcare facilities.
The proportion of HCA LD cases was higher in female compared with male cases 
(14.3% vs. 7.8%; p<0.01). The male-to-female ratio was lower in younger and 
older age groups (0.9:1 below 20 years and at 80 years and over), peaking at 2.2:1 
for those 40–49 years of age. When adjusting for age, sex, year and reporting 
country, females were more likely to have acquired their infection in a hospital 
compared with males (OR: 1.60, 95%CI: 1.49-1.71). Compared with those aged 
50-59 years, people younger than 20 years were twice as likely to be reported 
as HCA (OR: 2.04, 95%CI: 1.25-3.33). At 60 years of age and over, the risk of 
being reported as HCA increased with age peaking in those aged 80 years and 
over (OR: 4.58, 95%CI: 4.11-5.12).
Figure 9. Cumulative incidence of hotel and holiday rental accommodations sites associ-
ated with a further TALD case after control measures, by previous report status, EU/EEA, 
1 June 2011–31 December 2016. Source: Beauté, J. 2019 (102)
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Of the 4,859 culture-confirmed cases reported with a causative pathogen, 4,739 
(97.5%) were due to Legionella pneumophila. This proportion was similar in 
community-acquired and HCA LD cases (97.4% vs. 98.1%; p=0.31). Of the 4,533 
laboratory-confirmed cases due to L. pneumophila reported with a serogroup, 
4,137 (91.3%) were due to due to L. pneumophila serogroup 1. This proportion 
was higher in community-acquired cases compared with HCA LD cases (92.3% 
vs. 85.1%; p<0.01). Of the 107 community-acquired cases with culture confirma-
tion due to other Legionella species, 48 (44.9%) were due to L. longbeachae. No 
HCA LD case was reported with L. longbeachae. 
Of the 856 culture-confirmed cases due to L. pneumophila serogroup 1 isolates 
that were subtyped using monoclonal antibodies (MAb), 679 (79.3%) were MAb 
3/1 positive. This proportion was higher in community-acquired cases compared 
with HCA LD cases (83.6% vs. 43.3%; p<0.01).
Of the 32,379 cases with known outcome, 3,448 (10.7%) died. When adjusting 
for age, sex, year and reporting country, HCA LD cases were associated with a 
higher risk for fatal outcome compared with community-acquired cases (OR: 3.02, 
95%CI: 2.75-3.32).
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7 DISCUSSION
7.1 Main findings
7.1.1  Risk of TALD and under-ascertainment
In Study I, we estimated risk for TALD in most touristic destination countries in 
Europe. These findings are valuable because most similar studies rely on travel 
clinics, which are likely to miss LD cases (103). Steffen et al. provided health 
risk among travelers using logarithmic scales (104). Based on European data col-
lected in 2003, he estimated the TALD risk to be between 0.0001% and 0.001% 
per month of stay in developing countries. We found the highest risk associated 
with travel to Greece with 1.68 cases per 1 million nights. This corresponds to 
0.005% per month of stay, which is five times higher than Steffen’s estimate. We 
found the lowest risk estimate associated with travel to the UK (0.001% per month 
of stay). These results are compatible since travelers visiting developing countries 
are likely to be younger than those staying in Europe. 
Study I also revealed high levels of under-ascertainment in Austria, Germany, 
Greece, and Portugal. In all these countries, LD notification rate increased at 
a faster pace than the EU/EEA average during 2009–18. The EU/EEA average 
notification doubled during this 10-year period from 1.1 to 2.2 case per 100,000 
population (105). Over the same period, LD notification rate was multiplied by 
2.5 in both Austria and Portugal, by 3 in Germany, and by 4.3 in Greece. In 2012, 
Germany started reporting TALD cases to ELDSNet. Our findings did not trigger 
the increase observed in these countries but it confirmed that our results were sound. 
7.1.2 Community-acquired Legionnaires’ disease and weather 
conditions
In Study III, we confirmed the role of both rainfall and temperature as key environ-
mental factors associated with LD incidence. Previous studies in Europe and 
northern America reported similar findings (17, 19, 20, 23). The sequence of warm 
weather followed by heavy rainfall as conditions associated with high LD inci-
dence was also reported by a study carried out in the Netherlands (18). We found 
that the association between LD incidence and cumulative rainfall to have a linear 
shape. However, it seemed that unusually high temperatures were not associated 
with further increase in LD incidence.
7.1.3 Recurrence of TALD in hotels
In Study III, our results suggested that approximately 30% of hotels associated with 
TALD cluster were reported with at least one further case within two years. This 
proportion was comparable but higher than previous estimates made by a study 
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carried out during 1993–2000 (75). There may be two main reasons explain the 
difference. First, the ELDSNet database is more mature with more accommodation 
sites and therefore more likely to detect further cases. Second, surveillance of LD 
improved over the last decade and LD cases are now more likely to be reported 
to ELDSNet than they were 20 years ago. 
Our findings suggested that the risk of recurrence was independent of the measures 
taken after the detection of a TALD cluster.
7.1.4 Healthcare-associated Legionnaires’ disease
HCA LD disproportionally affects older people in Europe. Yet, HCA LD also con-
cerns younger age groups. LD cases in children below 20 years of age were twice 
more likely to be HCA cases compared to those people that are 50–59 year-olds. 
HCA LD were associated with less virulent strains of Legionella as suggested by 
earlier work (106).
HCA LD cases are more severe than community-acquired cases. Countries with 
less performant surveillance systems seemed to capture HCA LD more easily than 
cases associated with other settings. 
7.2 Strengths
7.2.1 Legionnaires’ disease surveillance data
The interpretation of any analysis based on surveillance data will depend on the 
validity of these notification data (56). Among the main factors that may create 
biases, most are unlikely to have a large impart of LD surveillance data. First, LD is 
a severe condition. It means that factors influencing health-seeking behaviors (e.g. 
distance to healthcare facilities or cost) will probably not change the probability 
for a case to seek medical care. Second, the case definition of LD includes clinical 
criteria (i.e. presence of pneumonia). Therefore, issues related to the possibility to 
diagnose asymptomatic cases of a disease (e.g. screening of chlamydia) are here 
irrelevant. Last, the vast majority (>90%) of LD cases in these surveillance data 
were classified as confirmed according to the EU case definition. This means that 
the laboratory test used to ascertain the diagnosis was highly specific. 
In both Study I and III we focused on TALD data, which are unique. Studies look-
ing at travel-associated infection in European travelers tend to focus on overseas 
destinations and exotic pathogens (107). Infections like LD, which are unlikely 
to be diagnosed in travel clinics and can be associated with domestic travel are 
usually overlooked (103).
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7.2.2 Pooling data from different countries
The other main strength of European LD surveillance data is its international 
component. All 30 EU/EEA Member States report data to the comprehensive 
notifications scheme and approximately 25 countries report to the near-real-time 
surveillance of TALD (22 EU/EEA Member States and three non-EU/EEA coun-
tries in 2015 (37)). All reporting countries use the same reporting protocol. These 
schemes allowed us to have large sample size for our studies. Although only four 
countries participated in study II, we were able to include approximately 8,000 
community-acquired cases, allowing adjustment at the regional level and analysis 
by month (108). We could also identify similarities and possible difference across 
countries in terms of LD environmental drivers. In study IV, we included more 
than 4,000 HCA LD cases, which allowed us to look at strains less commonly 
associated with LD.
Another advantage of pooling data from several countries is to allow comparison 
and benchmarking. In Study I, we took advantage of the data from Denmark, France, 
the Netherlands, and the UK to highlight under-ascertainment in other countries. 
Last, running analyses at the supranational level may help confirm hypotheses 
made at lower geographical level. In study II, we explored the contribution 
of different environmental factors, of which some had already been studied at 
national or regional level. However, it was difficult to understand whether the 
 differences observed between studies were real or explained by somehow  different 
methodologies.
7.3 Limitations
7.3.1 Surveillance data
For all studies, we used surveillance data, i.e. data generated for – at least partly 
– a purpose different from the research objectives. The use of secondary data can 
be problematic if the data are inadequate to answer the research question (109).
One of the main limitations of surveillance data is that there is always a risk of 
under-ascertainment of cases. First, physicians may fail to suspect LD and/or 
prescribe the laboratory test that will confirm the diagnosis. Reports from central 
and eastern European countries suggest that lack of clinician awareness could 
explain the low notification rates observed (110, 111). Second, cases may not be 
reported to the surveillance system. Many European countries carried out capture-
recapture studies to assess the magnitude of LD underreporting (112-114). If the 
factors influencing under-ascertainment are associated with either the exposure 
or the outcome of our studies, there may be an ascertainment bias. Although we 
thought this was unlikely, we adjusted our analyses by country.
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There are other issues with data quality of surveillance data, including completeness 
and validity (115). Completeness refers to the proportion of variables for which 
there are missing and/or unknown fields. Overall, data completeness was high for 
the variables included in our analyses. However, only a small proportion of cases 
were culture-confirmed (<15%). Since culture confirmation is the best method to 
characterize further LD strains, we could not fully describe the causative strains 
in Study IV. The validity of the data is the ability to represent the reality. In terms 
of validity, the main limitation of our studies is the possible misclassification of 
cases for the probable setting of infection. Although there is a European defini-
tion for TALD, there is currently no consensus for HCA LD. Community-acquired 
LD is a diagnosis of exclusion (i.e. non-HCA and non-travel). It is therefore for 
the epidemiologist registering cases to classify them according the most probable 
setting. Since investigating every sporadic case would be both costly and likely 
to yield negative results, there is no environmental investigation for most cases. 
Therefore, it is impossible to assess the level of misclassification. Yet, there are 
reasons to think this phenomenon is limited. . Most of all, LD is a rare event so 
any changes taking place before the incubation is likely to play a role in the infec-
tion (e.g. admission to hospital). 
Last, if pooling data from different countries present many advantages, it also 
poses a number of analytical and procedural problems related to heterogeneity 
(116). We can distinguish three main types of heterogeneity: 
a) Heterogeneity of surveillance systems refers to differences in the design and 
operation of surveillance (e.g. if some countries have a surveillance system 
covering only a few regions of their territory). Although LD surveillance 
systems differ across EU/EEA countries, there are important similarities. All 
countries but Belgium have a system with comprehensive coverage and LD 
is notifiable in all countries (92). The main problem is under-ascertainment of 
cases, especially in central and eastern European countries (see above). Yet, 
we do not think under-ascertainment in some countries introduced substantial 
biases in our analyses. There were no major changes during the periods con-
sidered in our studies and analyses of risk factors were adjusted (116). 
b) Heterogeneity in disease determinants refers to real epidemiological differences 
across countries (e.g. different exposure to risk factors). Exposure to weather 
conditions favourable to the growth of Legionella are likely to vary across 
country and even within countries. Thus, the overall risk is probably higher in 
southern Europe compared to nortern countries. Howver, the situation may be 
more complex as suggested by the increasing trend form west to east reported 
in France (117). Northern Italy and southern Switzerland seem to be region 
particularly favourable to high LD incidence (20, 108). Such heterogeneity 
is deemed problematic when the effectiveness of intervention differs across 
countries. In study III, we found no significant differences across countries in 
terms of effectiveness of control messures. 
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c) Heterogeneity of data quality refers to variation in terms of quality across 
countries (e.g. completeness is higher in country A compared to country B). 
For study II, we only included the four countries with sufficient data quality 
for the variable place of residence. For study IV, we excluded Sweden because 
its cases lacked inormation on the probable setting of infection.
7.3.2 Travel data
In study I, we used travel data provided by Eurostat (94). These data have limita-
tions. First, most countries collect these data through household surveys, which are 
at risk of recall bias. Second, the number of nights spent by destination countries 
were not available by age group. It is possible that EU/EEA residents aged over 
50 years (i.e. people at increased risk for LD) have different travel patterns than 
younger residents. This could have biased our findings. Eurostat data publishes 
travel data with delay. We ran our analysis for study I in 2011 but travel data were 
only available until 2009. 
There are alternative data sources for travel data but none was fully satisfactory at 
the time. Different methodologies used to capture travel patterns result in different 
estimations of traveler numbers (118). Recent studies used different data source 
to estimate travel patterns such as the International Air Transport Association 
(IATA) data (119). IATA data seem reliable but may miss a large part of European 
 travelers who stay in Europe or in their residence country.
7.3.3 Ecological fallacy
In study II, we looked at the association between environmental condition and 
the incidence of community-acquired LD. Data were aggregated at regional level 
(NUTS2). Since the study unit was a group of people rather than the individual, it 
can be qualified an ecological study (120). Such study is at risk of ecological fal-
lacy, i.e. assuming that the results found at group level are valid at individual level. 
To avoid such risk, we should have collected exposure data for all cases. In this 
case, it would have meant collecting individual exposure to meteorological condi-
tions for the nearly 8,000 cases included in the analysis, which was not possible. 
7.3.4 Censoring in survival analyses
In study III, accommodations were right-censored, i.e. censored because of study 
termination. Theoretically, this should pose no problem to the analysis if we can 
assume that the risk of occurrence of a further case was independent of the time 
of entry to the study (report of control measures after a cluster of TALD). If this 
is true, we could assume independent censoring (or non-informative censoring) 
(121). Yet, the number of TALD cases increased during 2011–15 for reasons that 
are not fully understood (37). It means that it is possible that the risk of occurrence 
of a further case increased during the study period. 
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7.3.5 Confounding
When the association between an exposure variable and the outcome is influenced 
by other factors or variables, there is risk to draw wrong conclusions because of 
confounding bias. Confounding occurs when a variable is associated with both 
exposure and outcome (97). However, a confounding variable is not part of the 
causal chain between exposure and outcome. In Study IV, age was a possible con-
founder. Old age is associated with both severe outcome (e.g. death) and probability 
to be HCA. We controlled for confounding by stratifying age in eight age groups.
7.4 Future perspectives
LD incidence has been increasing in both Europe and the USA. Individuals can 
risk will get LD even with low level of Legionella in the causative water system 
(122). In addition to known risk factors (e.g. age, male sex), some behavioral fac-
tors may be associated with LD infection. Such factors may be occupational (e.g. 
plumbing) or linked to daily activities such as showering or gardening. Futures 
studies should investigate further the role of these behavioral factors.
Outbreak investigations often yielded disappointing results. The use of WGS sug-
gested that LD outbreaks could be caused by several strains (122). The inclusion 
of molecular data in LD epidemiological studies could improve our understanding 
of LD transmission. 
Systematic collection of information on preventive and control measures, espe-
cially in surveillance schemes such as the ELDSNet surveillance of TALD could 
help determine the best options to prevent LD cases.
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8 CONCLUSIONS
Using data from the year 2009, Study I revealed high levels of under-ascertainment 
in Austria, Germany, Greece, and Portugal. It also provided fresh estimates of 
TALD risk among European travelers, which need regular updates (123).
Study II confirmed the impact of rainfall and temperature on LD incidence. This 
is of importance in a context in which there is increasing concern that climate 
change may lead to a higher incidence of LD (25, 124, 125). Yet, it is unclear 
whether behavioral factors could be associated with community-acquired cases 
and weather conditions. 
In Study III, we identified possible risk factors associated with TALD recurrence 
in hotels. These findings may help ELDSNet prevent TALD cases after detection 
of a cluster. In addition, we proposed several improvements to the surveillance 
scheme, especially regarding data collection. Information on Legionella strains and 
control measures should be more detailed and harmonized in order to understand 
whether some control measures are effective than others.
In study IV, we analyzed one of the largest data set of HCA LD to date. This 
allowed a precise description of the LD strains involved in HCA LD, especially 
less common strains such as L. pneumophila non-serogroup 1.
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